survivin蛋白在结直肠癌表达水平及与其临床关系的荟萃分析  

Clinicopathological Significance of Survivin Expression and Colorectal Cancer:a Meta Analysis

作　　者：孙国贵[1] 胡万宁[1] 王雅棣[2] 李成林[2] 杨从容[3] 

机构地区：[1]河北联合大学附属人民医院放化疗科,河北省唐山市063000 [2]北京军区总医院放疗科,北京市100700 [3]河北医科大学第四医院放疗科,河北省石家庄市050011

出　　处：《中华全科医学》2012年第9期1343-1344,1406,共3页Chinese Journal of General Practice

摘　　要：目的系统评价存活蛋白(survivin)表达水平在结直肠癌中表达水平及与其临床病理特征的关系。方法计算机检索Cochrane Libtary(2011年第1期),PubMed、CNKI等数据库,并辅以手工检索,评价质量及提取资料后采用Stata 11.0软件对数据库进行系统评价。结果 Meta分析结果显示:survivin在结直肠癌组及正常对照组[比值比(oddsratio,OR)=50.77,95%可信区间(confidence interval,CI)=22.69-113.62]的表达差异具有统计学意义(P<0.05)。临床病理结果显示:survivin在结直肠癌表达水平与患者性别、年龄、发病部位、肿瘤直径、dukes分期、有无淋巴结转移、分化程度及5年生存率无关(P>0.05),而与有无复发转移有关(P<0.05)。Spearman等级相关分析显示,survivin与Bcl-2蛋白阳性率在结直肠癌中表达具有相关性(r=0.313,P<0.01)。结论 survivin在结直肠癌中高表达,并且增加了其复发转移的危险,同时survivin与Bcl-2在结直肠癌发生也有一定的相关性。Objective To investigate survivin protein and risk factors in non-small cell colorectal cancer with a systematic review. Methods The published studies were searched in the Cochrane Libtary（ Issue 1,2011 ）, Pubmed and CNKI databases and other relevant journals were also handsearched. Then＇the quality of the included trials was assessed and meta-analysis was performed by Stata 11.0 software. Results As for the positive rate of survivin expression, significant differences were tested between colorectal cancer vs. normal tissues （ OR = 50.77,95 % CI = 22.69 - 113.62, P 〈 0.05 ）. No significant difference was tested between sex, age, tumor location, tumor length, dukes stage, lymph node metastasis, histologic subtype and the overall survival time （P 〉 0.05 ） respectively. There were significant differences between recurrence or metastasis vs. non-recurrence or metastasis （ P 〈 0.05 ）. Survivin expression was positively correlated with Bcl-2 （ r = 0.313, P 〈 0.01 ）. Conclusion Survivin expression in- creased recurrence or metastasis of coloreactal cancer, and meanwhile substantiaI correlation was confirmed between survivin and Bcl-2.

关 键 词：结直肠肿瘤 SURVIVIN BCL-2 META分析 

分 类 号：R735.35[医药卫生—肿瘤] R735.34[医药卫生—临床医学]